In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 2, 1996, Pages 514-519

  Dornsife, Ronna E ^a,b   Averett, Devron R ^b  

^a Burroughs Wellcome Co   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE; ACICLOVIR; ANTIVIRUS AGENT; DIDANOSINE; GANCICLOVIR; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW TOXICITY; BURST FORMING UNIT E; COLONY FORMING UNIT GM; DOSE RESPONSE; DRUG METABOLISM; DRUG POTENCY; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL;

EID: 0030040315     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.2.514     Document Type: Article

References (65)

1. Allan, J. D., K. J. Connolly, H. Fitch, L. Jackson-Pope, C. McLaren, R. Canetta, and J. E. Groopman. 1993 Long-term follow-up of didanosine administered orally twice daily to patients with advanced human immunodeficiency virus infection and hematologic intolerance of zidovudine. Clin. Infect. Dis. 16(Suppl. 1):S46-S51.
2. Barditch, P., B. Polsky, C. van der Horst, F. Ducanson, O. Kuye, D. Ganes, R. Faulkner, R. Raasch, D. Armstrong, B. Petty, B. Rae, A. Yacobi, C. Flexner, and R. Desjardins. 1992. Hematologic toxicity of FLT appears to be AUC dependent. Clin. Pharm. Ther. 51:170 abstr. OII-1).
3. Barditch-Crovo, P., D. Ganes, F. Duncanson, C. van der Horst, B. Polsky, B. Petty, R. Faulkner, O. Kuye, A. Yacobi, P. Lietman, C. Norden, and C. Flexner. 1992. Early markers of hematologic toxicity with FLT therapy, abstr. WeB 1012. p. We 47. In Abstract book, vol 1. VIII International Conference on AIDS/III STD World Congress. Harvard AIDS Institute, Cambridge.
4. Beris, P., and P. A. Miescher. 1988. Hematological complications of antiinfectious agents Semin. Hematol. 25:123-139.
5. Blum, M. R., S. H. T. Liao, S. S. Good, and P. de Miranda. 1988. Pharmacokinetics and bioavailability of zidovudine in humans. Am. J. Med. 85(Suppl. 2A):189-194
6. Bradley, T. R., and D. Metcalf. 1966. The growth of mouse bone marrow cells in vitro. Aust. J. Exp. Biol. Med. Sci. 44:287-299
7. Chamberlain, S. D., K. K. Biron, R. E. Dornsife, D. R. Averett, L. Beauchamp, and G. W. Koszalka. 1994. An enantiospecific synthesis of the human cytomegalovirus antiviral agent [(R)-3-((2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy)-4-hydrowbutyl] phosphonic acid. J. Med. Chem 37: 1371-1377.
8. Ching, S. V., K. M. Ayers, R. E. Dornsife, G. L. Grebe, and J. L. Howard. 1994 Nonclinical toxicology and in vitro toxicity studies with the novel anti-HIV agent (1S,4R)-4-[2-amino-6-(cylcopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (1592U89) succinate, abstr. I88, p. 92 In Program and abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy American Society for Microbiology, Washington, D.C.
9. Connolly, K. J., J. D. Allan, H. Fitch, L. Jackson-Pope, C. McLaren, R. Canetta, and J. E. Groopman. 1991 Phase I study of 2́-3́-dideoxyinosine administered orally twice daily to patients with AIDS or AIDS-related complex and hematologic intolerance to zidovudine. Am. J. Med 91:471-478.
10. Cooper, D. A., P. O. Pehrson, C. Pedersen, M. Moroni, E. Oksenhendler, W. Rozenbaum, N. Clumeck, V. Faber, W. Stille, B. Hirschel, C. Farthing, R. Doherty, J. M. Yeo, and a European-Australian Collaborative Group. 1993. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS-related complex: a double-blind, randomized trial. AIDS 7:197-207.
11. Daluge, S. M., D. J. M. Purifoy, P. M. Savina, M. H. St. Clair, N. R. Parry, I. K. Dev, P. Novak, K. M. Ayers, J. E. Reardon, G. B. Roberts, J. A. Fyfe, M. R. Blum, D. R. Averett, R. E. Dornsife, B. A. Domin, R. Ferone, D. A. Lewis, and T. A. Krenitsky. 1994 5-Chloro-2́,3́-dideoxy-3́-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profile. Antimicrob. Agents Chemother 38:1590-1603.
12. Deldar, A., and C. E. Stevens. 1993. Development and application of in vitro models of hematopoiesis to drug development. Toxicol Pathol. 21:231-240.
13. de Miranda, P., S. Weller, M. Maha, A. R. Lifson, M. A. Piccini, G. W. Rutherford, H. Hollander, and M. R. Blum. 1988. Pharmacokinetics of zidovudine (ZDV) and acyclovir (ACV) during concurrent drug administration in asymptomatic men with HIV infection. abstr. 3136, p. 253. In Program and abstracts, vol. 1 IV International Conference on AIDS
14. Donahue, R. E., M. M. Johnson, L. I. Zon, S. C. Clark, and J. E. Groopman. 1987. Suppression of in vitro haematopoiesis following human immunodeficiency virus infection. Nature (London) 326:200-203.
15. Dornsife, R. E., M. H. St. Clair, A. T. Huang, T. J. Panella, G. W. Koszalka, C. L. Burns, and D. R. Averett. 1991. Anti-human immunodeficiency virus synergism by zidovudine (3′-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob. Agents Chemother. 35:322-328
16. Doweiko, J. P., and J. E. Groopman. 1994. Hematological consequences of HIV infection, p. 617-628. In S. Broder, T. C. Merigan, Jr., and D Dolognesi (ed.), Textbook of AIDS medicine. The Williams & Wilkins Co., Baltimore.
17. Drach, J. C., L. B. Townsend, M. R. Nassiri, S. R. Turk, L. A. Coleman, R. V. Devivar, G. Genzlinger, E. D. Kreske, T. E. Renau, A. C. Westerman, C. Shipman, Jr., K. K. Biron, R. Dornsife, and E. R. Kern. 1992 Benzimidazole ribonucleosides: a new class of antivirals with potent and selective activity against human cytomegalovirus. Antiviral Res. 17(Suppl. 1):49 (abstr. 12)
18. Drusano, G. L., F. M. Balis, S. R. Gitterman, and P. A. Pizzo. 1994. Quantitative relationships between zidovudine exposure and efficacy and toxicity. Antimicrob. Agents Chemother. 38:1726-1731.
19. Du, D. L., D. A. Volpe, C. K. Grieshaber, and M. J. Murphy, Jr. 1990. In vitro myelotoxicity of 2′,3′-dideoxynucleosides on human hematopoietic progenitor cells. Exp. Hematol. 18:832-836.
20. Dudley, M. N., K. K. Graham, S. Kaul, S. Geletko, L. Dunkle, M. Browne, and K. Mayer. 1992. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J. Infect. Dis. 166:480-485.
21. Dunkle, L., A. Cross, R. Gugliotti, R. Martin, M. Browne, and H. Murray. 1990. Dose-escalating study of safety and efficacy of dideoxy-didehydrothymidine (d4T) for HIV infection. Antiviral Res. April(Suppl. 1):116 (abstr. 145).
22. Faraj, A., D. A. Fowler, E. G. Bridges, and J.-P. Sommadossi. 1994. Effects of 2′,3′-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38:924-930.
23. Fischl, M. A., C. B. Parker, C. Pettinelli, M. Wulfsohn, M. S. Hirsch, A. C. Collier, D. Antoniskis, M. Ho, D. D. Kichman, E. Fuchs, T. C. Merigan, R. C. Reichman, J. Gold, N. Steigbigel, G. S. Leoung, S. Rasheed, A. Tsiatis, and the AIDS Clinical Trials Group. 1990. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. N. Engl. J. Med. 323:1009-1014.
24. Flexner, C., C. van der Horst, M. A. Jacobson, W. Powderly, F. Duncanson, D. Ganes, P. A. Barditch-Crovo, B. G. Petty, P. A. Baron, D. Armstrong, P. Bricmont, O. Kuye, A. Yacobi, R. DesJardins, and B. Polsky. 1994. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials J. Infect. Dis 170:1394-1403.
25. Furman, P. A., M. Davis, D. C. Liotta, M. Paff, L. W. Frick, D. J. Nelson, R. E. Dornsife, J. A. Wurster, L. J. Wilson, J. A. Fyfe, J. V. Tuttle, W. H. Miller, L. Condreay, D. R. Averett, R. F. Schinazi, and G. R. Painter. 1992. The anti-hepatitis B activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxthiolane-5-yl]cytosine. Antimicrob. Agents Chemother 36:2686-2692.
26. Ganser, A., J. Greher, B. Volkers, S. Staszewski, and D. Hoelzer. 1989. Inhibitory effect of azidothymidine, 2′-3′-dideoxyadenosine, and 2′-3′ dideoxycytidine on in vitro growth of hematopoietic progenitor cells from normal persons and patients with AIDS. Exp. Hematol. 17:321-325
27. Gosselin, G., R. F. Schinazi, J.-P. Sommadossi, C. Mathe, M.-C. Bergogne, A.-M. Aubertin, A. Kirn, and J.-L. Imbach. 1994. Anti-human immunodeficiency virus activities of the β-L-enantiomer of 2′,3′-dideoxycytidine and its 5-fluoro derivative in vitro. Antimicrob. Agents Chemother. 38:1292-1297
28. Henderson, J. R. 1989. Use of ganciclovir in the treatment of cytomegalovirus infections. Br. J. Clin Pract. 43:231-237.
29. Horikoshi, A., and M. J. Murphy, Jr. 1982. Comparative effects of chemotherapeutic drugs on human and murine hematopoietic progenitors in vitro Chemotherapy (Basel) 28:480-501.
30. Irons, R. D. (ed.). 1985 Toxicology of the blood and bone marrow. Target organ toxicology series. Raven Press, New York.
31. Jacobson, M. A., P. deMiranda, D. M. Cederberg, T. Burnette, E. Cobb, H. R. Brodie, and J. Mills. 1987 Human pharmacokinetics and tolerance of oral ganciclovir Antimicrob. Agents Chemother. 31:1251-1254.
32. Johnson, M., T. Caiazzo, J.-M. Molina, R. Donohue, and J. Groopman. 1988. Inhibition of bone marrow myelopoiesis and crythropoiesis in vitro by antiretroviral nucleoside derivatives. Br. J. Haemtol. 70:137-141
33. Kern, E. R. 1990. Preclinical evaluation of antiviral agents: in vitro and animal model testing, p. 87-94. In G J. Galasso, R J Whitley, and T. C Mcrigan (ed.), Antiviral agents and viral diseases of man, 3rd ed. Raven Press, New York.
34. Klecker, R. W., Jr., J. M. Collins, R. C. Yarchoan, R. Thomas, N. McAtee, S. Broder, and C. E. Myers. 1988. Pharmacokinetics of 2′,3′-dideoxycytidine in patients with AIDS and related disorders. J Clin. Pharmacol. 28:837-842.
35. Knupp, C. A., W. C. Shyu, R. Dolin, F. T. Valentine, C. McLaren, R. R. Martin, K. A. Pittman, and R. H. Barbhaiya. 1991. Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex. Clin. Pharmacol. Ther. 49:523-535.
36. Marsh, J. C. 1976 The effects of cancer chemotherapeutic agents on normal hematopoietic precursor cells. a review. Cancer Res. 36:1853-1882.
37. Matthews, T., and R. Boehme. 1988. Antiviral activity and mechanism of action of ganciclovir. Rev. Infect. Dis. 10(Suppl. 3):490-494.
38. McGuffin, R. W., F. M. Shiota, and J. D. Meyers. 1980. Lack of toxicity of acyclovir to granulocyte progenitor cells in vitro Antimicrob Agents Chemother 18:471-473.
39. Mitsuya, H., and R. Yarchoan. 1994. Development of antiretroviral therapy for AIDS and related disorders, p. 721-742. In S. Broder, T. C. Mengan, Jr., and D Bolognesi (ed.), Textbook of AIDS medicine. The Williams & Wilkins Co , Baltimore
40. Monod, J., J.-P. Changeux, and F. Jacob. 1963. Allosteric proteins and cellular control systems. J. Mol. Biol. 6:306-329.
41. Murray, H. W., K. E. Squires, W. Weiss, S. Sledz, H. S. Sacks, J. Hassett, A. Cross, R. E. Anderson, and L. M. Dunkle. 1995. Slavudine in patients with AIDS and AIDS-related complex: AIDS clinical trials group 089. J. Infect. Dis. 171(Suppl 2):S123-S130
42. Painter, G. R., M. H. St. Clair, P. de Miranda, D. Reynolds, S. Ching, R. Dornsife, D. J. Livingston, S. Pazhanisamy, and R. Tung. 1995. An overview of the preclinical development of the HIV protease inhibitor VX-478 (141W94), abstr. LB5, p. 167. In Program and abstracts of 2nd National Conference on Human Retroviruses and Related infections. American Society for Microbiology Books International, Herndon, Va.
43. Parchment, R. E., M. Huang, and C. L. Erickson-Miller. 1993 Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicol Pathol. 21:241-250
44. Parchment, R. E., D. A. Volpe, P. M. LoRusso, C. L. Erickson-Miller, M. J. Murphy, Jr., and C. K. Grieshaber. 1994. In vitro-in vitro correlation of myelotoxicity of 9-methoxypyrazoloacridine (NSC-366140, PD115934) to myeloid and crythroid hematopoietic progenitors from human, murine, and canine marrow. J. Natl. Cancer Inst. 86:273-280.
45. Parker, L. M., J. M. Lipton, N. Binder, E. L. Crawford, M. Kudisch, and M. J. Levin. 1982 Effect of acyclovir and interferon on human hematopoietic progenitor cells Antimicrob. Agents Chemother. 21:146-150.
46. Physician's Desk Reference. 1994. Cytovene® (ganciclovir), p. 2357-2361. Physician's desk reference, vol. 48 Medical Economics Co. Inc , Oradell, N.J.
47. Physician's Desk Reference. 1994 Retrovir® (zidovudme), p. 742-746. Physician's desk reference, vol. 48 Medical Economics Co. Inc., Oradell, N.J.
48. Pluda, J. M., T. P. Cooley, J. S. G. Montaner, L. E. Shay, N. E. Reinhalter, S. N. Warthan, J. Ruedy, H. M. Hirst, C. A. Vicary, J. B. Quinn, G. J. Yuen, M. A. Wainberg, M. Rubin, and R. Yarchoan. 1995. A phase I/II study of 2′deoxy-3′thiacytidine (Lamivudine) in patients with advance human immunodeficiency virus infection. J. Infect Dis. 171:1438-1447
49. Richman, D. D., M. A. Fischl, M. H. Grieco, M. S. Gottlieb, P. A. Volberding, O. L. Laskin, J. M. Leedom, J. E. Groopman, D. Mildvan, M. S. Hirsch, G. G. Jackson, D. T. Durack, S. Nusinoff-Lehrman, and the AZT Collaborative Working Group. 1987. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex, a double-blind placebo-controlled trial. N. Engl J Med 317:192-197.
50. Schinazi, R. F., A. McMillan, D. Cannon, R. Mathis, R. M. Lloyd, A. Peck, J.-P. Sommadossi, M. St. Clair, J. Wilson, P. A. Furman, G. Painter, W.-B. Choi, and D. C. Liotta. 1992. Selective inhibition of human immunodeficiency viruses by racemates and enantromers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cylosine. Antimicrob. Agents Chemother. 36:2423-2431.
51. Scott, R., S. Follansbee, R. Olson, R. Pollard, W. Reiter, M. Salgo, et al. 1993. Safety and tolerance of zalcitabine (ddC. Hivid®) in a double-blind comparative trial (ACTG 114 N3300). abstr PO-B26-2115, p. 487. In Program and abstracts, vol I IX International Conference on AIDS. Wellcome Foundation Ltd., London.
52. Sommadossi, J.-P. 1993 Nucleoside analogs: similarities and differences. Clin. Infect. Dis. 16(Suppl. 1):S7-S15.
53. Sommadossi, J. P., D. W. Barnes, L. R. Miller, M. A. Markiewicz, and R. J. Whitley. 1987. Novel pharmacologic strategies in the treatment of life-threatening infections: clinical experience with 9-(1,3-dihydroxy-2-propoxy-methyl)-guanine (DHPG). Clin. Res. 35:491A
54. Sommadossi, J.-P., and R. Carlisle. 1987. Toxicity of 3′-azido-3′-deoxythymidine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine for normal human hematopoietic progenitor cells in vitro. Antimicrob. Agents Chemother. 31:452-454.
55. Sommadossi, J.-P., R. F. Schinazi, C. K. Chu, and M.-Y. Xie. 1992. Comparison of cytotoxicity of the (-)- and (+)-enantiomer of 2′,3′-dideoxy-3′-thiacytidine in normal human bone marrow progenitor cells Biochem. Pharmacol. 44:1921-1925.
56. Sommadossi, J.-P., Z. Zhu, R. Carlisle, M.-Y. Xie, and D. A. Weidner. 1990. Pharmacologic studies of nucleosides active against the human immunodeficiency virus Ann. N. Y. Acad. Sci. 616:356-366.
57. Spearman, C. 1904. The proof and measurement of association between two things. Am. J. Psychcol. 15:72-101.
58. Stretcher, B. N., A. J. Pesce, P. T. Frame, K. A. Greenberg, and D. S. Stern. 1994. Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS 8:763-769.
59. Szczech, G. 1996. Preclinical development of antiviral drugs. Clin Infect. Dis. 22:355-360.
60. van Draanen, N. A., M. Tisdale, N. R. Parry, R. Jansen, R. E. Dornsife, J. V. Tuttle, D. R. Averett, and G. W. Koszalka. 1994. Influence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosides. Antimicrob. Agents Chemother. 38:868-871.
61. van Holde, K. E. (ed.). 1971. Multiple equilibria, p 62-67. In Physical biochemistry Prentiss-Hall, Englewood Cliffs, N.J.
62. Wingard, J. R., A. D. Hess, R. K. Stuart, R. Saral, and W. H. Burns. 1983. Effect of several antiviral agents on human lymphocyte functions and marrow progenitor cell proliferation. Antimicrob. Agents Chemother 23:593-597.
63. Yarchoan, R., C. F. Perno, R. V. Thomas, R. W. Klecker, J.-P. Allain, R. J. Wills, N. McAtee, M. A. Fischl, R. Dubinsky, M. C. McNeely, H. Mitsuya, J. M. Pluda, T. J. Lawley, M. Leather, B. Safai, J. M. Collins, C. E. Myers, and S. Broder. 1988. Phase I studies of 2′,3′-dideoxycytidine in severe human immunodeficiency virus infection as a single agent and alternating with zidovudine (AZT). Lancet i:76-80.
64. Youle, M. S., B. G. Gazzard, M. A. Johnson, D. A. Cooper, J. F. Hoy, H. Busch, B. Ruf, P. D. Griffiths, S. L. Stephenson, M. Dancox, and A. R. Bell on behalf of the European-Australian Acyclovir Study Group. 1994 Effects of high-dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double-blind, placebo-controlled study. AIDS 8:641-649.
65. Zhu, Z., M. J. M. Hitchcock, and J.-P. Sommadossi. 1991. Metabolism and DNA interaction of 2′,3′-didehydro-2′,3′-dideoxythymidine in human bone marrow cells. Mol Pharmacol. 40:838-845